PURPOSE: To report globe salvage rates, @entity1 survival and adverse events of ophthalmic artery chemosurgery (OAC) for International Classification of @entity995 (ICRB) group D @entity995 (naive and after prior failures). METHODS: Single institution retrospective review of all Group D eyes treated with OAC from 5/2006-12/2012. @entity1 were treated according to our previously-published techniques. Primary outcome was globe retention without need for external beam radiotherapy (EBRT). Demographics, prior treatments, OAC agents used, and adverse events were also recorded. RESULTS: 112 group D eyes (103 @entity1 ) that underwent OAC were included (average follow-up was 34 months, range: 2-110 months). 47 eyes were treatment-na  ve, 58 eyes received prior treatments elsewhere, and 7 young @entity1 (7 eyes) underwent our published "bridge therapy" (single agent intravenous @entity3003 ) until old enough to undergo OAC. Median number of OAC sessions/eye was 3 (range 1-9). 110/112 eyes received intra-arterial melphalan, but only 31 eyes received @entity3601 alone. 43 eyes received @entity3003 , and 78 eyes received @entity1945 (never as a single agent). 80/112 eyes received >1 drug over their treatment course, and 39 eyes received all three agents. 24 eyes (16 pretreated, 7 treatment-na  ve, 1 bridge) failed treatment and required enucleation during the study period. Enucleation and EBRT were avoided in 88/112 eyes (78.6%; including 40/47 [85.1%] treatment-na  ve eyes, 42/58 [72.4%] previously-treated eyes, and 6/7 eyes [85.7%] among bridge @entity1 ). By Kaplan-Meier survival analysis, globe salvage rate was 74% at 110 months among all @entity1 , and 85% at 110 months in the treatment-na  ve subgroup. Transient grade 3/4 @entity1398 was more common in @entity1 receiving OAC bilaterally. No @entity1 died of metastatic disease. CONCLUSIONS: OAC is effective for curing group D @entity995 , achieving rates of globe salvage many times higher than systemic chemotherapy (10-47%), even in eyes that previously failed other treatments. OAC can be performed multiple times, using multiple agents, on one or both eyes of @entity1 .

Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'infants', 'child'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity3601 :: ('MESH:D008558', 'Chemical') :: ['melphalan'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1945 :: ('MESH:D019772', 'Chemical') :: ['topotecan'] @entity995 :: ('MESH:D012175', 'Disease') :: ['Retinoblastoma', 'retinoblastoma']
@entity995 :: (MESH:D012175,Disease) :: ['Retinoblastoma']
